AskGene Pharma, Inc.
5 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma (NCT06206733) | AskGene Pharma, Inc. | 2024-01-25 |
| A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors (NCT05509985) | AskGene Pharma, Inc. | 2023-08-09 |
| A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. (NCT05867420) | AskGene Pharma, Inc. | 2023-08-02 |
| ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer. (NCT05632939) | AskGene Pharma, Inc. | 2023-02-21 |
| A Study of ASKG315 in Patients With Advanced Solid Tumors. (NCT05554666) | AskGene Pharma, Inc. | 2022-10-15 |
Track AskGene Pharma, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.